Amgen Inc. buy melinda
Start price
31.08.17
/
50%
€159.06
Target price
12.09.17
€171.38
Performance (%)
7.96%
End price
12.09.17
€171.72
Summary
This prediction ended on 12.09.17 with a price of €171.72. The BUY prediction by melinda finished with a performance of 7.96%. melinda has a follow-up prediction for Amgen Inc. where he still thinks Amgen Inc. is a Buy. melinda has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Amgen Inc. | 1.641% | 1.641% | 8.928% | 13.687% |
| iShares Core DAX® | 0.191% | 4.892% | 22.046% | 64.626% |
| iShares Nasdaq 100 | -0.614% | 2.901% | 7.804% | 109.421% |
| iShares Nikkei 225® | 0.599% | 7.404% | 22.218% | 57.591% |
| iShares S&P 500 | -0.036% | 3.489% | 4.833% | 68.003% |
Comments by melinda for this prediction
In the thread Amgen Inc. diskutieren
zu folgen
$
Wenn in Phase III getestet Kopf an Kopf, das Bestreben, reduziert KYPROLIS und Dexamethason das Sterberisiko um 21% und erhöhte die Überlebenszeit von 7,6 Monaten im Vergleich zu Velcade und Dexamethason in Patienten mit rezidivierendem oder refraktärem multiplem Myelom